安旭生物: 民生证券股份有限公司关于杭州安旭生物科技股份有限公司2024年度持续督导工作现场检查报告

Core Viewpoint - The report indicates that Hangzhou Anxu Biotechnology Co., Ltd. has maintained a sound governance structure and effective internal controls during the continuous supervision period, with no violations in fundraising, related transactions, or operational status [1][5]. Group 1: Company Governance and Internal Control - The company’s articles of association and governance systems are complete and effectively executed [2]. - The board of directors, supervisors, and senior management fulfill their responsibilities as required [2]. - Internal control systems are effectively implemented [2]. Group 2: Information Disclosure - The company has fulfilled its information disclosure obligations accurately and completely, with no false records or misleading statements [2][5]. Group 3: Independence and Related Party Transactions - The company maintains independence in assets, personnel, finance, and business, with no violations regarding the occupation of company funds by related parties [3][4]. Group 4: Fundraising and Usage - The company has adhered to fundraising management regulations, with funds stored in dedicated accounts and no unauthorized changes in usage [3][4]. Group 5: Related Transactions and Investments - There are no violations regarding external guarantees, related transactions, or significant external investments during the supervision period [4][5]. Group 6: Operational Status - The company’s business model and structure have not undergone significant adverse changes, and its operational status remains normal [4][5]. Group 7: Compliance and Recommendations - The company is advised to continue improving its governance structure and ensure timely information disclosure while managing fundraising effectively [5].